Repression of oxidative stress/reactive metabolite regulated gene expression is associated with conversion of carbamazepine into a hepatotoxicant in LPS and DSS rat models

Angelique M. Leone, Erin Saleh, S. Jim Proctor, Michael F. Kelley, L. Mark Kao, Lynn Varacallo, Peter Taggart, Jean McCarthy, Monica Singer, Michael McMillian

Drug Safety Sciences, Janssen Pharmaceutical Research and Development, LLC, Raritan, USA.

DOI: 10.4236/abb.2014.53028                

Abstract

Idiosyncratic hepatotoxicity accounts for many drug failures in the clinic and is a leading cause for black-boxed and withdrawn drugs. This toxicity has proven difficult to predict preclinically, but correlates with oxidative stress/reactive metabolites (OS/RM). As noted previously for antiepileptic compounds, many drugs causing idiosyncratic adverse drug effects are detected by OS/RM gene expression responses in the rat. In the present study, two immune activation models, low dose lipopolysaccharide (1 mg/kg IV) and 5% dextran sulphate sodium (DSS) in drinking water, were examined to determine if either would convert the non-toxic idiosyncratic toxicant carbamazepine (225 mg/kg) into a rat hepatotoxicant at 24 hours. Using the low dose LPS model, about 1/3 of the carbamazepine-treated rats either showed robust ALT and AST elevations with histopathological evidence of hepatotoxicity, or died. Rats in this LPS/carbamazepine group were subdivided based on ALT values into non-responders, responders or robust responders. Whereas most carbamazepine-induced mRNAs were repressed by LPS across all rats in this group, the OS/ RM genes aflatoxin aldehyde reductase (Afar) and glutathione transferase Ya (Gstya) were repressed only in the robust responder subgroup; it is unclear whether repression of these genes contributes to or results from hepatotoxicity. The OS/RM gene microsomal epoxide hydrolase (mEphx) showed repression across all rats. NAD(P)H: menadione oxidoreductase (Nmor) is an OS/RM-responsive gene that is also induced by LPS, confounding interpretation of its changes. After pretreatment with 5% DSS at 24 hours or for 5 days, using a protocol that reportedly produces increased endotoxin absorption, carbamazepine was not converted to a hepatototoxicant in any rats. Instead, DSS produced a pronounced (2- to 6-fold) and selective potentiation of carbamazepine induction of OS/RM-responsive mRNAs. The lack of repressive effects of DSS on these mRNAs or in converting carbamazepine to a hepatotoxicant was not due to desensitization of endotoxin responses since LPS was at least as effective when administered to DSS-pretreated rats. OS/RM gene repression may contribute to development of hepatotoxicity of carbamazepine in immune activation models.

Keywords

Hepatotoxicity; Gene Expression; Oxidative Stress/Reactive Metabolites (OS/RM); LPS; DSS

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Bond, C.A. and Raehl, C.L. (2006) Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals, pharmacotherapy. The Journal of Human Pharmacology and Drug Therapy, 26, 735-747. http://dx.doi.org/10.1592/phco.26.6.735
[2]	Olsen, K.M., Rebuck, J.A., Weidenbach, T. and Fish, D.N. (2000) Pharmacokinetics of intravenous trovafloxacin in critically Ill adults, pharmacotherapy. The Journal of Human Pharmacology and Drug Therapy, 20, 400-404. http://dx.doi.org/10.1592/phco.20.5.400.35056
[3]	Bharadwaj, M., Illing, P., Theodossis, A., Purcell, A.W. Rossjohn, J. and McCluskey, J. (2012) Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annual Review of Pharmacology and Toxicology, 52, 401-431. http://dx.doi.org/10.1146/annurev-pharmtox-010611-134701
[4]	Uetrecht, J. (2007) Idiosyncratic drug reactions: Current understanding. Annual Review of Pharmacology and Toxicology, 47, 513-539. http://dx.doi.org/10.1146/annurev.pharmtox.47.120505.105150
[5]	Srivastava, A., Maggs, J.L., Antoine, D.J., Williams, D.P., Smith, D.A. and Park, B.K. (2008) Role of reactive metabolites in drug-induced hepatotoxicity. Handbook Exp Pharmacology, 196,165-194.
[6]	Evans, D.C., Watt, A.P., Nicoll-Griffith, D.A. and Baillie, T.A. (2003) Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chemical Research in Toxicology, 17, 3-16. http://dx.doi.org/10.1021/tx034170b
[7]	Obach, R.S., Kalgutkar, A.S., Soglia, J.R. and Zhao, S.X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chemical Research in Toxicology, 21, 1814-1822. http://dx.doi.org/10.1021/tx034170b
[8]	Leone, A.M., Kao, L.M., McMillian, M.K., Nie, A.Y., Parker, J.B., Kelley, M.F., Usuki, E., Parkinson, A., Lord, P.G. and Johnson, M.D. (2007) Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chemical Research in Toxicology, 20, 600-608. http://dx.doi.org/10.1021/tx600351g
[9]	Lu, W., Li, X. and Uetrecht, J.P. (2008) Changes in gene expression induced by carbamazepine and phenytoin: Testing the danger hypothesis. Journal of Immunotoxicology, 5, 107-113. http://dx.doi.org/10.1080/15476910802085723
[10]	Morio, L.A., Leone, A., Sawant, S.P., Nie, A.Y., Brandon Parker, J., Taggart, P., Barron, A.M., McMillian, M.K. and Lord, P. (2006) Hepatic expression of heme oxygenase-1 and antioxidant response element-mediated genes following administration of ethinyl estradiol to rats. Toxicology and Applied Pharmacology, 216, 416-425. http://dx.doi.org/10.1016/j.taap.2006.06.016
[11]	Xu, J.J., Henstock, P.V., Dunn, M.C., Smith, A.R., Chabot, J.R. and de Graaf, D. (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicological Sciences, 105, 97-105. http://dx.doi.org/10.1093/toxsci/kfn109
[12]	Pirmohamed, M., Kitteringham, N.R., Breckenridge, A.M. and Park, B.K. (1992) Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. British Journal of Clinical Pharmacology, 33,183-186. http://dx.doi.org/10.1111/j.1365-2125.1992.tb04022.x
[13]	Zou, W., Roth, R.A. and Ganey, P.E. (2012) Animal models of idiosyncratic, drug-induced liver injury: Emphasis on the inflammatory stress hypothesis, Encyclopedia of drug metabolism and interactions. John Wiley & Sons, Inc., Hoboken.
[14]	Morgan, E.T., Goralski, K.B., Piquette-Miller, M., Renton, K.W., Robertson, G.R., Chaluvadi, M.R., Charles, K.A., Clarke, S.J., Kacevska, M., Liddle, C., Richardson, T.A., Sharma, R. and Sinal, C.J. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition, 36, 205-216. http://dx.doi.org/10.1124/dmd.107.018747
[15]	Deng, X., Stachlewitz, R.F., Liguori, M.J., Blomme, E.A.G., Waring, J.F., Luyendyk, J.P., Maddox, J.F., Ganey, P.E. and Roth, R.A. (2006) Modest inflammation enhances diclofenac hepatotoxicity in rats: Role of neutrophils and bacterial translocation. Journal of Pharmacology and Experimental Therapeutics, 319, 1191-1199. http://dx.doi.org/10.1124/jpet.106.110247
[16]	Masubuchi, Y. and Horie, T. (2004) Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metabolism and Disposition, 32, 437-441. http://dx.doi.org/10.1124/dmd.32.4.437
[17]	Leone, A., McMillian, M., Proctor, J., Kao, M., Troisi, J., Fermier, A., Varacallo, L., Taggart, P., McCarty, J., Sawant, S., Collins, A., Nie, A., Taylor, E., Lord, P. and Kelley, M. (2008) Idiosyncratic hepatotoxicity: A rat Model of Converting Oxidative Stress/Reactive Metabolites to Hepatotoxicants. Society of Toxicologic Pathology Annual Meeting (47th), Seattle, Washington, 16-20 March.
[18]	McMillian, M.K., Leone, A.M., Kelley, M.F., Proctor, S.J.E., Kao, L.M., Troisi, J., Fermier, A., Varacallo, L., Taggart, P. and McCarty, J. (2008) Toxicogenomics, oxidative stress and hepatotoxicity. Proceedings of 17th International Symposium on Microsomes and Drug Oxidations, 17, 25-30.
[19]	Vicario, M., Crespí, M., Franch, à., Amat, C., Pelegrí, C. and Moretó, M. (2005) Induction of colitis in young rats by dextran sulfate sodium. Digestive Diseases and Sciences, 50, 143-150. http://dx.doi.org/10.1007/s10620-005-1292-y
[20]	Vicario, M., Amat, C., Rivero, M., Moretó, M. and Pelegrí, C. (2007) Dietary glutamine affects mucosal functions in rats with mild dss-induced colitis. The Journal of Nutrition, 137, 1931-1937.
[21]	McMillian, M., Nie, A., Parker, J.B., Leone, A., Kemmerer, M., Bryant, S., Herlich, J., Yieh, L., Bittner, A., Liu, X., Wan, J., Johnson, M.D. and Lord, P. (2005) Drug-induced oxidative stress in rat liver from a toxicogenomics perspective. Toxicology and Applied Pharmacology, 207, 171-178. http://dx.doi.org/10.1016/j.taap.2005.02.031
[22]	McMillian, M., Nie, A.Y., Parker, J.B., Leone, A., Bryant, S., Kemmerer, M., Herlich, J., Liu, Y., Yieh, L., Bittner, A., Liu, X., Wan, J. and Johnson, M.D. (2004) A gene expression signature for oxidant stress/reactive metabolites in rat liver. Biochemical Pharmacology, 68, 2249-2261. http://dx.doi.org/10.1016/j.bcp.2004.08.003
[23]	Waring, J.F., Liguori, M.J., Luyendyk, J.P., Maddox, J.F., Ganey, P.E., Stachlewitz, R.F., North, C., Blomme, E.A.G. and Roth, R.A. (2006) Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. Journal of Pharmacology and Experimental Therapeutics, 316, 1080-1087. http://dx.doi.org/10.1124/jpet.105.096347
[24]	Blazka, M.E., Wilmer, J.L., Holladay, S.D., Wilson, R.E. and Luster, M.I. (1995) Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicology and Applied Pharmacology, 133, 43-52. http://dx.doi.org/10.1006/taap.1995.1125
[25]	Luyendyk, J.P., Maddox, J.F., Cosma, G.N., Ganey, P.E., Cockerell, G.L. and Roth, R.A. (2003) Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. Journal of Pharmacology and Experimental Therapeutics, 307, 9-16. http://dx.doi.org/10.1124/jpet.103.054288
[26]	Dickmann, L.J., Patel, S.K., Rock, D.A., Wienkers, L.C. and Slatter, J.G. (2011) Effects of interleukin-6 (IL-6) and an anti-il-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metabolism and Disposition, 39, 1415-1422.
[27]	Dallas, S., Sensenhauser, C., Batheja, A., Singer, M., Markowska M., Zakszewski, C., Mamidi, R.N.V.S., McMillia, M., Han, C., Zhou, H. and Silva, J. (2012) De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes. Current Drug Metabolism, 13, 923-929. http://dx.doi.org/10.2174/138920012802138589
[28]	Pirmohamed, M., Kitteringham, N.R., Guenthner, T.M., Breckenridge, A.M. and Park, B.K. (1992) An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochemical Pharmacology, 43, 1675-1682. http://dx.doi.org/10.1016/0006-2952(92)90696-G
[29]	Ketter, T.A., Frye, M.A., Corá-Locatelli, G., Kimbrell, T.A. and Post, R.M. (1999) Metabolism and excretion of mood stabilizers and new anticonvulsants. Cellular and Molecular Neurobiology, 19, 511-532. http://dx.doi.org/10.1023/A:1006990925122
[30]	Yip, V.L., Marson, A.G., Jorgensen, A.L., Pirmohamed, M. and Alfirevic, A. (2012) HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clinical Pharmacology & Therapeutics, 92, 757-765. http://dx.doi.org/10.1038/clpt.2012.189
[31]	Rath, H.C., Schultz, M., Freitag, R., Dieleman, L.A., Li, F.L., Linde, H.-J., Schölmerich, J. and Sartor, R.B. (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infection and Immunity, 69, 2277-2285. http://dx.doi.org/10.1128/IAI.69.4.2277-2285.2001
[32]	Damman, C.J., Miller, S.I., Surawicz, C.M. and Zisman, T.L. (2012) The microbiome and inflammatory bowel disease: Is there a therapeutic role for fecal microbiota transplantation[quest]. The American Journal of Gastroenterology, 107, 1452-1459. http://dx.doi.org/10.1038/ajg.2012.93